CA-SERVICENOW,-INC.
7.7.2020 13:32:12 CEST | Business Wire | Press release
ServiceNow (NYSE:NOW), the leading digital workflow company that makes work, work better for people, today announced that Paul Smith has joined the company as Senior Vice President and General Manager, EMEA, effective July 7, 2020. Smith joins the company from Salesforce, where he held a number of pan EMEA roles and most recently served as Executive Vice President and UK General Manager.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200707005309/en/
Smith brings to ServiceNow 17 years’ experience in leadership and senior management roles in the technology industry, with a track record in leading sales, go-to-market operations and developing new markets to drive triple digit growth.
“ServiceNow is leading the workflow revolution as companies worldwide transform themselves into modern digital enterprises,” said ServiceNow CEO Bill McDermott. “The best leaders and top talent want to work for companies like ServiceNow, where they can create the future. We are thrilled to have Paul Smith join our team, serve our customers and lead our EMEA region to new heights on our journey to becoming the defining enterprise software company of the 21st century.”
Smith will lead a region that includes many of the company’s most important markets and growth opportunities. ServiceNow’s EMEA revenues grew 32 percent in 2019 over the prior year; EMEA achieved an approximately $1 billion revenue run-rate as of Q1 2020.
“ServiceNow is the workflow leader and one of the most exciting and innovative growth companies in the world,” Smith said. “The pristine nature of the single Now Platform gives ServiceNow that rare combination of scale with agility. It’s this exact blend that customers are demanding of their critical partners as they wrestle with digitally transforming their businesses to navigate the change that is yet to come.”
Smith continued: “There are moments in your life when career defining opportunities present themselves; ServiceNow is one of those for me. The talented workforce and commitment to customer and partner success sets it apart from other global brands. I’m thrilled to join and privileged to have the opportunity to lead the EMEA business during the next phase of growth.”
Smith succeeds Phillip van der Wilt who served in this role from January 2016 to July 2020. During this time, and under van der Wilt’s leadership, the EMEA business grew rapidly and established ServiceNow’s strong foothold across EMEA.
“Many thanks to Philip for his leadership in growing our EMEA region over the past four years and establishing ServiceNow as a strategic partner to many of the world’s leading companies,” said Kevin Haverty, ServiceNow’s Executive Vice President of Worldwide Sales. “With Paul on our team, we are set to continue our momentum and drive the next phase of growth. Paul’s strong experience and exceptional track record across the region will help ensure ServiceNow accelerates our leadership as the partner of choice for C-suite leaders driving digital transformation.”
Smith began his career with Procter and Gamble but soon followed a passion for the technology industry that took him to Microsoft and leadership of a number of innovative start-up businesses. He joined Salesforce in 2012 to lead their EMEA Marketing Cloud business, before going on to lead EMEA Cloud Sales until his appointment as EVP and GM UK&I in February 2019.
About ServiceNow
ServiceNow (NYSE: NOW) is making the world of work, work better for people. Our cloud-based platform and solutions deliver digital workflows that create great experiences and unlock productivity for employees and the enterprise. For more information, visit: www.servicenow.com .
© 2020 ServiceNow, Inc. All rights reserved. ServiceNow, the ServiceNow logo, Now, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries. Other company names, product names, and logos may be trademarks of the respective companies with which they are associated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005309/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom